enoxaparin sodium / Generic mfg. - LARVOL DELTA

Extended venous thromboembolism prophylaxis after bariatric surgery does not increase postoperative bleeding complications. (PubMed, Surgery) - "Use of extended venous thromboembolism prophylaxis for all patients undergoing bariatric surgery is safe, with no differences in bleeding complications or emergency department visits. Future studies will aim to assess the impact that extended prophylaxis has on venous thromboembolism rates."

Journal • Cardiovascular • Venous Thromboembolism

A massive overdose of 6,600mg enoxaparin and its treatment with protamine (ASH 2025) - "There was no significant decrease in hemaglobin nor was blood product transfusion required. This case demonstrates the use of protamine sulfate amidst a paucity of guidelines for its use in massive enoxaparin overdosing cases, for which we propose the conservative use of protamine guided by aPTT as a possible managementregime."

Osteoarthritis

When pregnancy, HIT, and stroke collide: Navigating complex thrombotic care in a community-based setting (ASH 2025) - "Case Presentation: A 30-year-old woman, gravida 1 para 0, with a history of unprovoked lower extremity deep vein thrombosis (DVT) on chronic rivaroxaban for secondary prophylaxis was transitioned to low-molecular-weight heparin (enoxaparin) upon confirmation of pregnancy at 7 weeks' gestation...Enoxaparin was discontinued, and argatroban was initiated post-EVT, later transitioning to subcutaneous danaparoid, and ultimately fondaparinux for the remainder of her pregnancy...Another important feature of this case is that it was successfully managed entirely within a regional community hospital system, allowing the patient to stay close to her family and access local rehabilitation services. This case report highlights the ability of community-based hospitals to provide high-acuity, patient-centered care through strong interdisciplinary collaboration."

Cardiovascular • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Thrombocytopenia • Thrombosis

Navigating triple therapy in a high-risk cardiac patient with a covered stent and embolic stroke: A case report (ASH 2025) - "He was diagnosed with NSTEMI, and was initiated on aspirin, clopidogrel, enoxaparin, and nitroglycerin...Persistent cardiogenic shock necessitated Impella CP support, vasopressors (epinephrine, norepinephrine), and inotropes (dobutamine)...Following readmission, neurological evaluation revealed small subacute infarcts, following which anticoagulation with enoxaparin (later apixaban) was initiated alongside DAPT (aspirin, clopidogrel)...Repeat coronary angiography plays a major role here, allowing physicians to assess stent integrity and to make informed decision about de-escalation or continuation of therapy. Unfortunately, there are no current guidelines specifically addressing management strategies for patients with coronary artery aneurysms and recent embolic stroke, underscoring an urgent need for further research in this area."

Case report • Clinical • Cardiomyopathy • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Congestive Heart Failure • Depression • Heart Failure • Hematological Disorders • Ischemic stroke • Nephrology • Peripheral Arterial Disease • Pulmonary Disease • Renal Disease • Respiratory Diseases • Thrombosis

Inferior vena cava agenesis presenting as iliofemoral deep vein thrombosis in a 49-year-old male (ASH 2025) - "Case Presentation We present the case of a 49-year-old man with a past medical history of hypertension managed with losartan and impaired glucose tolerance treated with metformin...He was started on enoxaparin and later transitioned to rivaroxaban for outpatient anticoagulation...Conclusion This case underscores the diagnostic and therapeutic challenges in managing iliofemoral DVT due to IVC agenesis. Early identification and intervention can lead to favorable outcomes, particularly with the use of endovascular techniques and comprehensive follow-up."

Cardiovascular • CNS Disorders • Developmental Disorders • Hematological Disorders • Hypertension • Thrombosis • Venous Thromboembolism

Recurrent splenic infarction in triple-positive antiphospholipid syndrome despite therapeutic anticoagulation (ASH 2025) - "She was discharged on Apixaban. This case highlights the rarity of splenic infarction as an initial presentation of triple-positive APS. Although APS is commonly associated with thromboembolic events, splenic involvement is unusual and maybe easily overlooked. The patient's progression of infarcts, despite a therapeutic INR raised concern for possible warfarin resistance, a rare but important consideration in triple-positive APS."

Atrial Fibrillation • Cardiovascular • Genetic Disorders • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Ischemic stroke • Obstetrics • Thrombocytopenia • Vasculitis

Evolving catastrophic antiphospholipid syndrome with intracerebral hemorrhage: Treatment with plasma exchange and rituximab (ASH 2025) - "Apixaban was discontinued; enoxaparin 1 mg/kg twice daily, aspirin, prednisone 1 mg/kg with taper, and rituximab 375 mg/m² weekly ×4 were initiated...He was bridged from enoxaparin to warfarin (INR goal 2–3) for indefinite anticoagulation given APS and atrial fibrillation...Given higher recurrent thrombosis with direct oral anticoagulants reported in highrisk APS, vitamin K antagonists remain preferred for longterm therapy when feasible; multidisciplinary coordination is essential to individualize immunomodulation, anticoagulant selection, and timing. Disclaimer The views expressed in this abstract are those of the author(s) and do not necessarily reflect the official policy or position of the Defense Health Agency, the Department of Defense, or the U.S. Government."

Acute Kidney Injury • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Complement-mediated Rare Disorders • Genetic Disorders • Hematological Disorders • Immunology • Inflammatory Arthritis • Ischemic stroke • Nephrology • Renal Disease • Thrombocytopenia • Thrombosis

Management of acute coronary syndrome and surgical revascularization in a patient with severe Hemophilia A on emicizumab (ASH 2025) - "Following an initial diagnosis of non-ST elevation myocardial infarction (MI), he received aspirin and therapeutic enoxaparin with FVIII replacement to mitigate bleeding risk. Shortly afterward, his clinical status deteriorated to an ST elevation MI, necessitating the addition of clopidogrel and use of emergent fibrinolytic therapy with further FVIII replacement to target a trough FVIII activity above 100% in the immediate post-lysis period...This case highlights the complex interplay between HA and ACS, balancing thrombotic and bleeding risks, as well as the nuances of lab monitoring for patients on emicizumab. Early identification of these high-risk patients and transfer to a facility with access to specialized laboratory monitoring and multidisciplinary care are required to optimize patient outcomes."

Clinical • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Hemophilia • Hemophilia A • Human Immunodeficiency Virus • Infectious Disease • Myocardial Infarction • Rare Diseases • Rheumatology • Thrombosis

Vmx-C001 has no effect on the anticoagulant function of heparin in healthy subjects (ASH 2025) - "This study tested the anticoagulant effects of UFH and LMWH administered shortlyafter VMX-C001 in healthy subjects in situations simulating (a) patients taking FXa DOACs who requirerestoration of coagulation with VMX-C001 and then require UFH, e.g., for cardiopulmonary bypass; and(b) patients receiving VMX-C001 who then require LMWH for thromboprophylaxis. This Phase I, single site, open-label study in healthy subjects (aged ≥18–49 years) investigatedthe effects of VMX-C001, in combination with the FXa DOAC rivaroxaban and alone, on the anticoagulanteffect of UFH (UFH cohort) and LMWH (enoxaparin; LMWH cohort), respectively. In the UFH cohort (N=7), mean age was 28±8 years, 5 (71.4%) were female and all were non-Hispanic white. Following UFH alone on day 1, changes from baseline at 1 hr post-UFH: PT, aPTT and ACTincreased, dPT +16.41 sec and dRVVT -2.85 sec; TG decreased to undetectable levels (-100% vs. baseline).Four hrs after rivaroxaban administration on day 4:..."

Clinical • TINCR

Extended duration anticoagulation in cancer associated thrombosis (ASH 2025) - "Prophylactic dose of anticoagulation wasdefined as apixaban 2.5mg BD, rivaroxaban 10mg OD or enoxaparin 40mg OD (20mg OD for weight<50kg). Low dose anticoagulation is used in clinical practice for secondary thromboprophylaxis in patients withCAT without a signal for increased VTE recurrence and with low bleeding complications. Further data arerequired on the longer-term continuation of this thromboprophylactic strategy in an era when patientsare living longer with advanced cancer."

Oncology • Thrombosis

primary thromboprophylaxis using direct oral anti-coagulants (DOAC) in malignant pediatric tumors with vascular compression (ASH 2025) - "Sarangi previously demonstrated a reduction inthrombotic events for patients with mediastinal masses and tumor-related vascular compression (TRVC)who received prophylactic enoxaparin (Sarangi et...Fourteen patients (≥12 years and >40 kg) receivedapixaban (2.5 mg twice a day) and 5 patients received rivaroxaban (weight-based dosing)...On apixaban, 1 patient had rapid self-resolution of epistaxis, and another had hematuria withconcurrent ifosfamide administration...Though limited by its mostly retrospective design, small sample size, and single-institution population,our study highlights an at-risk subgroup of pediatric oncology patients with TRVC that may benefit fromuniversal primary thromboprophylaxis with a DOAC. Larger studies are needed to evaluate this further."

Clinical • Desmoid Tumors • Fibrosis • Hematological Malignancies • Lymphoma • Neuroblastoma • Obesity • Oncology • Pediatrics • Sarcoma • Solid Tumor • Venous Thromboembolism

C1-INH and atiii inhibit vaso-occlusion and vascular inflammation in sickle cell disease mice (ASH 2025) - "Adding enoxaparin to ATIII enhanced ATIIIprotection...In addition, plasma IL-6 levels 4 h after H/R was decreased (P<0.001) bytreatment of VOC with C1-INH or ATIII as compared to vehicle. These data suggest that inhibitingthrombo-inflammatory pathways with serpins may be a viable therapeutic strategy for VOC in SCD."

Preclinical • Genetic Disorders • Hematological Disorders • Inflammation • Sickle Cell Disease • CD31 • IL6 • PECAM1

Venous thromboembolism and bleeding rates in pregnant and postpartum patients with sickle cell disease (ASH 2025) - "Existing data on VTE and bleeding risks have significant limitations with a wide range ofreported VTE incidence and limited reporting of anticoagulant thromboprophylaxis or aspirin (ASA) use,SCD phenotype, and pregnancy characteristics...At the time of VTE diagnosis, 3 patients were taking ASA and 1was prescribed 40mg enoxaparin daily... Forty eligible patients with 60 pregnancies were identified and included in the analytic cohort.70% (28/40) identified as Black or African American and 18% (7/40) identified as Hispanic. Median age atdelivery was 33.8 years (IQR: 27.4-36.7), and median pre-pregnancy BMI was 24.7 kg/m2 (IQR: 22.7-28.4).Genotypes included HbSS (63%, 25/40), HbSC (23%, 9/40), HbSβ0 (8%, 3/40), HbSβ+ (5%, 2/40), andHbS/Quebec-Chori (3%, 1/40). Antepartum or postpartum thromboprophylaxis was prescribed in only15% (95% CI: 7-29%, 9/60) of pregnancies, predominantly for history of VTE (n=8/9)."

Clinical • Cardiovascular • Genetic Disorders • Hematological Disorders • Postpartum Hemorrhage • Respiratory Diseases • Sickle Cell Disease • Venous Thromboembolism

Use of apixaban for the prevention of thrombosis in children with coronary artery aneurysms secondary to kawasaki disease (ASH 2025) - "After at least 6 months of enoxaparin and/or warfarin,patients are eligible to transition to weight-based, twice-daily apixaban. This descriptive, retrospective chart review highlights the real-world use of apixaban forthromboprophylaxis in high-risk KD patients with large coronary artery aneurysms or dilation. Despitethe small sample size and limited follow-up, our findings suggest that apixaban is a safe and effectiveoption in this population. However, important limitations remain."

Clinical • Heart Failure • Hematological Disorders • Myocardial Ischemia • Thrombosis

Real-world analysis of thromboprophylaxis use during autologous hematopoietic stem cell transplantation for lymphoma and multiple myeloma (ASH 2025) - "We reported the use of VTE ppx in multiple myeloma (MM) patients during autologous HSCT (autoHSCT)where longer duration of VTE ppx was associated with VTE prevention and enoxaparin (LMWH) wassuperior to heparin (UFH)...VTE ppx did not increase HE. LMWH was superior to heparin andduration of VTE ppx reduced risk of VTE."

Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Transplantation

Safety and effectiveness of standard versus extended duration of anticoagulation in children with acute lymphoblastic leukemia and venous thrombo-embolism (ASH 2025) - "Pegaspargase was the mostcommon asparaginase used (91%).Index VTE occurred at a median of 75 days (IQR: 25-182) following ALL diagnosis...The preferred initial agent was enoxaparin (101/106, 95%) and medianduration of anticoagulation was 6.4 months (IQR: 3.2-9.5)... VTE progression/recurrence following a first VTE occurred in 17% of children andadolescents with ALL. In this retrospective analysis, extended anticoagulation was not associated with areduced risk of VTE progression/recurrence. This could suggest that an extended anticoagulationapproach is not more effective or could reflect confounding by indication where patients considered athigher risk of progression/recurrence received longer antithrombotic treatment."

Clinical • Acute Lymphocytic Leukemia • Cerebral Hemorrhage • CNS Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Venous Thromboembolism

Application of dorsal skin fold chamber microvascular thrombosis model in JAK2V617F mice (ASH 2025) - "Overcoming the limitations of other models, JAK2VF and JAK2VF/VF mice can undergo DSFCimplantation without excessive mortality or bleeding. Weight was found to be associated with %microvascular occlusion in JAK2VF mice. At 2 h after TNF-α infusion, JAK2V617F+ mice exhibit increasedmicrovascular occlusion; anticoagulation with enoxaparin prevents occlusion."

Preclinical • Anesthesia • Cardiovascular • Hematological Disorders • Myeloproliferative Neoplasm • Thrombosis • CD31 • JAK2 • PECAM1 • TNFA

Congenital factor II deficiency presenting with recurrent thrombosis (ASH 2025) - "Shewas treated with enoxaparin for three months, supported by FFP by two times a week while she was onenoxaparin...Genetic diagnosis is essential to clarify the phenotype, and itmay guide treatment. This case emphasizes the need for individualized management andmultidisciplinary care in patients with complex coagulation disorders."

Cardiovascular • CNS Disorders • Epilepsy • Hematological Disorders • Metabolic Disorders • Thrombosis • Women's Health • F2 • MTHFR

Epidemiologic clues, current management and diagnostic trends in idiopathic budd-chiari syndrome: Implications of PNH and diagnostic testing (ASH 2025) - "Coumadin was the most commonchronic anticoagulant, given to 52% of patients, followed by DOACs (38%), and enoxaparin (10%).In sum, our study provides a definitive etiologic landscape of BCS and further delineates the nature ofthe relationship between PNH and BCS. Critically, our results reveal a significant proportion of patientswith BCS for whom causative therapy is available."

Clinical • Cardiovascular • Genetic Disorders • Hematological Disorders • Hepatology • Thrombosis • JAK2

Impact of thrombocytopenia on hemorrhage and recurrent thrombosis in patients with cancer associated thrombosis, a time varying analysis (ASH 2025) - "Most patients (89.8%) received anticoagulation following theirindex VTE, including apixaban (51.4%), enoxaparin (29.0%) and rivaroxaban (8.5%). The severity ofthrombocytopenia directly parallels the risk of major bleeding and thrombotic recurrence, yet even mildreductions in platelet count markedly elevate these risks. Incorporating thrombocytopenia into risk-stratification tools and tailoring anticoagulation strategies accordingly will be essential for safelymanaging this frequent clinical challenge."

Clinical • Gastric Cancer • Gastrointestinal Cancer • Hepatology • Nephrology • Oncology • Renal Disease • Respiratory Diseases • Solid Tumor • Thrombocytopenia • Thrombosis • Venous Thromboembolism

Current practices of anticoagulant utilization in pediatric patients with acute myeloid leukemia (AML) (ASH 2025) - "Evaluated anticoagulants included lowmolecular weight heparins, the oral thrombin inhibitors, oral factor Xa inhibitors, and the vitamin Kantagonist warfarin. Continuous anticoagulants, such as unfractionated heparin and bivalirudin, wereexcluded due to their role in complex critical care outside of the management of thrombosis...Enoxaparin was the most frequentlyutilized anticoagulant (150/171; 87.7%) followed by rivaroxaban (22 patients; 12.9%)...Anticoagulation practices for pediatric patients with AML vary widely by institution. Bleeding prevalencewas not found to be greater among patients receiving presumed prophylaxis compared to patients whoreceived anticoagulation to treat TE, and those who did not receive anticoagulation. This suggests theremay be a role for safe utilization of prophylaxis in high-risk patients."

Clinical • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Pediatrics • Respiratory Diseases • Thrombocytopenia • Venous Thromboembolism

A quality improvement project to optimize VTE prophylaxis in surgical patients (ASH 2025) - "It appears each time a providerorders VTE prophylaxis (heparin or enoxaparin), displaying the institutional algorithm to guidecorrect agent and dosing based on weight, renal function, and VTE risk.The pre-intervention period spanned January to September 2024, and the post-intervention periodcovered October 2024 to July 2025...Real-time decision support, targetededucation, and comprehensive audit-feedback contributed to a sustained improvement in adherence toprophylaxis guidelines. Future work will evaluate whether the intervention led to a reduction in actual VTEevents, explore the use of artificial intelligence to predict risk and guide prophylaxis decisions, and focuson sustaining the improvement and scaling the model to other hospitals across the country."

Clinical • Cardiovascular • Hematological Disorders • Venous Thromboembolism • Women's Health

Cell-free DNA is associated with central venous catheter-associated deep venous thrombosis in critically ill children (ASH 2025) - "CRETE was a multicenter, phase 2b randomizedtrial of prophylactic enoxaparin compared to no anticoagulation for primary prevention of CVC-associated DVT... cfDNA levels on the day of CVC insertion are associated with CVC-associated DVT in criticallyill children. Ongoing analysis of other markers of NETosis will further investigate the association betweenNETs and pediatric CVC-associated DVT, the role of inflammation in the development of DVT in children,and whether targeted therapies to block NETs would reduce thrombotic risk."

Cell-free DNA • Clinical • Cardiovascular • Hematological Disorders • Inflammation • Thrombosis

BH10 Nailing the diagnosis. (PubMed, Br J Dermatol) - "This patient had further cutaneous findings of systemic amyloid, with haemorrhagic bullae secondary to enoxaparin administration evident on his abdomen. This case highlights that it is worth considering amyloid in one's differential diagnosis when patients present with nail findings such as described above, and assessing for other organ involvement."

Journal • Amyloidosis • Cardiac Amyloidosis • Cardiovascular • Dermatology • Diabetes • Melanoma • Metabolic Disorders • Mood Disorders • Musculoskeletal Pain • Oncology • Respiratory Diseases • Solid Tumor • Type 2 Diabetes Mellitus

Association between the Use of Fondaparinux Plus Radial Access and Clinical Outcomes in Patients with Non-ST Elevation Acute Coronary Syndrome. (PubMed, Arq Bras Cardiol) - "The combination of fondaparinux and radial access was associated with the lowest rates of MACE and major bleeding, compared to either strategy alone."

Clinical data • Journal • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction